Inhibition of tumor-associated fatty acid synthase activity enhances vinorelbine (Navelbine®)-induced cytotoxicity and apoptotic cell death in human breast cancer cells

Oncology Reports

Volumn 12, Issue 2, 2004, Pages 411-422

  Menendez, Javier A ^a,b   Colomer, Ramon ^c   Lupu, Ruth ^a,b  

^a Evanston Northwestern Research Institute   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c HOSPITAL JOSEP TRUETA   (Spain)

Author keywords

Apoptosis; Breast cancer; Cerulenin; Chemotherapy; Fatty acid synthase; Vinorelbine

Indexed keywords

ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; CERULENIN; COLORING AGENT; DNA; DRUG DERIVATIVE; FATTY ACID SYNTHASE; NAVELBINE; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE; VINBLASTINE;

APOPTOSIS; ARTICLE; BIOSYNTHESIS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG POTENTIATION; HUMAN; IC 50; METABOLISM; TIME; TUMOR CELL LINE;

ANTIBIOTICS, ANTIFUNGAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL LINE, TUMOR; CERULENIN; COLORING AGENTS; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FATTY ACID SYNTHETASE COMPLEX; HUMANS; INHIBITORY CONCENTRATION 50; TETRAZOLIUM SALTS; THIAZOLES; TIME FACTORS; VINBLASTINE;

EID: 9544244568     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.12.2.411     Document Type: Article

References (54)

1. Kuhajda FP, Piantadosi S and Pasternack GR: Haptoglobin-related protein (Hpr) epitopes in breast cancer as a predictor of recurrence of the disease. N Engl J Med 321: 636-641, 1989. (Pubitemid 19221307)
2. Corrigan C, Martin AW, Lear SC, Kuhns S, Kuhajda FP and Pasternack GR: Prognostic value of the immunohistochemical demonstration of haptoglobin-related protein in breast cancer. Am J Clin Pathol 96: 406, 1991.
3. Jensen V, Holm-Nielsen P and Meisen F: OA-519 expression in node negative breast cancer. Breast Cancer Res Treat 27: 1-2, 1993.
4. Kuhajda FP, Jenner K, Wood FD, Hennigar RA, Jacobs LB, Dick JD and Pasternack GR: Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci USA 91: 6379-6383, 1994. (Pubitemid 24200664)
5. Alo PL, Visca P, Marci A, Mangoni A, Botti C and Di Tondo U: Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer 77: 474-482, 1996. (Pubitemid 26047568)
6. Alo PL, Visca P, Trombetta G, Mangoni A, Lenti L, Monaco S, Botti C, Serpieri DE and Di Tondo U: Fatty acid synthase (FAS) predictive strength in poorly differentiated early breast carcinomas. Tumori 85: 35-40, 1999. (Pubitemid 29196243)
7. Alo PL, Visca P, Framarino ML, Botti C, Monaco S, Sebastiani V, Serpieri DE and Di Tondo U: Immunohistochemical study of fatty acid synthase in ovarian neoplasms. Oncol Rep 7: 1383-1388, 2000.
8. Gansler TS, Hardman W III, Hunt DA, Schaffel S and Hennigar RA: Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. Hum Pathol 28: 686-692, 1997. (Pubitemid 27258421)
9. Shurbaji MS, Kalbfleisch JH and Thurmond TS: Immunohistochemical detection of a fatty acid synthase (OA-519) as a predictor of progression of prostate cancer. Hum Pathol 27: 917-921, 1996. (Pubitemid 26304570)
10. Swinnen JV, Vanderhoydonc F, Elgamal AA, Eelen M, Vercaeren I, Joniau S, van Poppel H, Baert L, Goossens K, Heyns W and Verhoeven G: Selective activation of the fatty acid synthesis pathway in human prostate cancer. Int J Cancer 88: 176-179, 2000.
11. Kuhajda FP: Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 16: 202-208, 2000.
12. Weiss L, Hoffman GE, Schreiber R, Andres H, Fuchs E, Korber E and Kolb HJ: Fatty-acid biosynthesis in man, a pathway of minor importance. Purification, optimal assay conditions, and organ distribution of fatty acid synthase. Biol Chem Hoppe Seyler 267: 905-912, 1986.
13. Ookhtens M, Kannan R, Lyon I and Baker N: Liver and adipose tissue contributions to newly formed fatty acids in an ascites tumor. Am J Physiol 247: R146-R153, 1984. (Pubitemid 14090895)
14. Pizer ES, Wood FD, Pasternack GR and Kuhajda FP: Fatty acid synthase (FAS): a target for cytotoxic antimetabolites in HL60 promyelocytic leukemia cells. Cancer Res 56: 745-751, 1996. (Pubitemid 26055462)
15. Vance D, Goldberg I, Mitsuhashi O and Bloch K: Inhibition of fatty acid synthethases by the antibiotic cerulenin. Biochem Biophys Res Commun 48: 549-565, 1972.
16. Omura S: The antibiotic cerulenin: a novel tool for biochemistry as an inhibitor of fatty acid synthesis. Bact Rev 40: 681-697, 1976.
17. Christie WW, Hunter ML and Clegg RA: The effects of cerulenin on lipid metabolism in vitro in cellular preparation from the rat. Biochim Biophys Acta 666: 284-290, 1981. (Pubitemid 12200282)
18. Funabashi H, Kawaguchi A, Tomoda H, Omura S, Okuda S and Iwasaki S: Binding site of cerulenin in fatty acid synthetase. J Biochem 105:751-755, 1989. (Pubitemid 19134450)
19. Moche M, Schneider G, Edwards P, Dehesh K and Lindqvist Y: Structure of the complex between the antibiotic cerulenin and its target, β-ketoacyl carrier protein synthase. J Biol Chem 274: 6031-6034, 1999. (Pubitemid 29111003)
20. Pizer ES, Jackisch C, Wood FD, Pasternack GR, Davidson NE and Kuhajda FP: Inhibition of fatty acid synthase induces programmed cell death in human breast cancer cells. Cancer Res 56: 2745-2747, 1996. (Pubitemid 26175731)
21. Pizer ES, Chrest FJ, Di Giuseppe JA and Han WF: Pharmacological inhibition of mammalian fatty acid synthase suppress DNA replication and induce apoptosis in tumor cell lines. Cancer Res 58: 4611-4615, 1998. (Pubitemid 28480625)
22. Pizer ES, Thupari J, Han WF, Pinn ML, Chrest FJ, Ffehywot GL, Townsend CA and Kuhajda FP: Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res 60: 213-218, 2000. (Pubitemid 30070736)
23. Li JN, Gorospe M, Chrest FJ, Kumaravel TS, Evans MK, Han WF and Pizer ES: Pharmacological inhibition of fatty acid synthase activity produces both cytostatic and cytotoxic effects modulated by p53. Cancer Res 61: 1493-1499, 2001. (Pubitemid 34292578)
24. Pizer ES, Wood FD, Heine HS, Romantsev FE, Pasternack GR and Kuhajda FP: Inhibition of fatty acid synthase delays disease progression in a xenograft model of ovarian cancer. Cancer Res 56: 1189-1193, 1996. (Pubitemid 26080952)
25. Zhou XJ and Rahmani R: Preclinical and clinical pharmacology of vinca alkaloids. Drugs 44 (Suppl 4): 1-16; 66-69, 1992.
26. Krikorian A and Breillout F: Vinorelbine (Navelbine). A new semisynthetic vinca alkaloid. Onkologie 14: 7-12, 1991.
27. Budman DR: Vinorelbine (Navelbine): a third-generation vinca alkaloid. Cancer Invest 15: 475-490, 1997.
28. Gregory RK and Smith IE: Vinorelbine - a clinical review. Br J Cancer 82: 1907-1913, 2000. (Pubitemid 30326449)
29. Domenech GH and Vogel CL: A review of vinorelbine in the treatment of breast cancer. Clin Breast Cancer 2: 113-128, 2001. (Pubitemid 32771563)
30. Berenbaum MC: What is synergy? Pharmacol Rev 41: 93-141, 1989.
31. Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
32. Chou TC, Riedeout D, Chou J and Bertino JR: Chemotherapeutic synergism, potential and antagonism. In: Encyclopedia of Human Biology. Vol. 2. Dulbecco R (ed). Academic Press, San Diego, CA, pp371-379, 1991.
33. Chou TC: The median-effect principle and the combination index for quantitation of synergism and antagonism. In: Synergism and Antagonism in Chemotherapy. Chou TC and Rideout DC (eds). Academic Press, San Diego, CA, pp61-102, 1991.
34. Chou TC, Motzer RJ, Tong Y and Bosl GJ: Computerized quantitation of synergism and antagonism of taxol, topotecan and cisplatin against teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 86: 1517-1524, 1994. (Pubitemid 24330215)
35. Chou J and Chou TC: Dose-effect analysis with microcomputers: quantitation of ED50, LD50, synergism, antagonism, low-dose risk, receptor-ligand binding and enzyme kinetics (Manual and Software. Bio-soft, Cambridge, UK, 1987.
36. Chou J and Chou TC: Quantitation of synergism and antagonism of two or more drugs by computerized analysis. In: Synergism and Antagonism in Chemotherapy. Chou TC and Rideout DC (eds). Academic Press, San Diego, CA, pp223-244, 1991.
37. Dils R and Carey EM: Fatty acid synthase from rabbit mammary gland. Methods Enzymol 35: 74-83, 1975.
38. Wang LG, Liu XM, Kreis W and Budman DR: The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol 44: 355-361, 1999. (Pubitemid 29455579)
39. Maltzman W and Czyzyk L: UV irradiation stimulates levels of p53 cellular tumor antigen in non-transformed cells. Mol Cell Biol 4: 1689-1694, 1984. (Pubitemid 14008276)
40. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B and Craig R: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6301, 1991.
41. Fritsche M, Haessler C and Brandner G: Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 8: 307-318, 1993. (Pubitemid 23073746)
42. Nelson WG and Kastan MB: DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol 14: 1815-1823, 1994. (Pubitemid 24074576)
43. El-Deiry WS, Tokino T, Veculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993. (Pubitemid 23346378)
44. Harper JW, Adami GR, Wei N, Keyomarsi K and Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potential inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816, 1993. (Pubitemid 23346377)
45. Waga S, Hannon GJ, Beach D and Stillman B: The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369: 574-578, 1994. (Pubitemid 24192528)
46. El-Deiry WS, Harper JW, O'Connot PM, Velculescu VE, Canman CE, Jacman J, Pietenpol JA, Burrel M, Hill DE, Wang Y, Wiman KG, Mercer WE, Kastan MB, Kohn KW, Elledge SJ, Kinzler KW and Vogelstein B: WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54: 1169-1174, 1994. (Pubitemid 24108052)
47. Kip1, BRCA1, and NF-κB. Int J Oncol 24: 591-608, 2004.
48. Blagosklonny MV and Fojo T: Molecular effects of paclitaxel: myths and reality. Int J Cancer 83: 151-156, 1999. (Pubitemid 29449089)
49. Yu D, Jing T, Liu B, Yao J, Tan M, McDonnell TJ and Hung MC: Overexpression of ErbB2 blocks taxol-induced apoptosis by upregulation of p21(cip1), which inhibits p34(Cdc2) kinase. Mol Cell 2: 581-591, 1998. (Pubitemid 128379084)
50. Barboule N, Chadebech P, Baldin V, Vidal S and Valette A: Involvement of p21 in mitotic exist after paclitaxel treatment in MCF-7 breast adenocarcinoma cell lines. Oncogene 15: 2867-2875, 1997. (Pubitemid 28004576)
51. Li W, Fan J, Banerjee D and Bertino JR: Overexpression of p21(waf1) decreases G2-M arrest and apoptosis induced by paclitaxel in human sarcoma cells lacking both p53 and functional Rb protein. Mol Pharmacol 55: 1088-1093, 1999. (Pubitemid 29252376)
52. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW and Vogelstein B: Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497-1501, 1998.
53. Blagosklonny MV, Robey R, Bates S and Fojo T: Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs. J Clin Invest 105: 533-539, 2000. (Pubitemid 30127254)
54. Kuhajda FP, Pizer ES, Li JN, Mani NS, Frehywot GL and Townsend CA: Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc Natl Acad Sci USA 288: 2379-2381, 2000. (Pubitemid 30448165)